Estudo experimental da inibição da proliferação vitreorretiniana pelo uso da hiperecina

Machado, Roberto Augusto Fernandes; Casella, Antônio Marcelo Barbante; Malaguido, Marcus Rudolph; Oguido, Ana Paula Miyagusko Taba

doi:10.1590/s0004-27492009000500010

Cited by 5 publications

(4 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intravitreal injections of hypericin in a PVR rabbit model ameliorated the PVR outcome following a single injection of the drug 73. Another more recent study using a PVR ocular trauma model also showed a benefit for hypericin in decreasing PVR progression 74. Tyrosine kinase inhibitors like herbimycin A have also been tested in a rabbit PVR model.…”

Section: Current and Emerging Treatments For Proliferative Vitreoretimentioning

confidence: 99%

Proliferative vitreoretinopathy: current and emerging treatments

Sadaka¹,

Giuliari²

2012

OPTH

View full text Add to dashboard Cite

Proliferative vitreoretinopathy is a disease process that follows the proliferation of ectopic cell sheets in the vitreous and/or periretinal area, causing periretinal membrane formation and traction, in patients with rhegmatogenous retinal detachments. Currently, vitreous surgery is the standard treatment; however, the results aren’t satisfactory given the vision loss that ensues and that redetachment is relatively common. It is becoming clearer that there exists an interplay between various cytokines/growth factors, matrix proteins, and the different cell types that drive the undesirable formation of periretinal membranes. This fundamental understanding is aiding in identifying different adjunct agents that can block the cellular events intrinsic to proliferative vitreoretinopathy. In this review, we describe the current understanding on the pathogenesis and discuss how the fundamental understanding of the biochemical/molecular events is instrumental in developing the novel treatment strategies that are also highlighted.

show abstract

Section: Current and Emerging Treatments For Proliferative Vitreoretimentioning

confidence: 99%

Proliferative vitreoretinopathy: current and emerging treatments

Sadaka¹,

Giuliari²

2012

OPTH

View full text Add to dashboard Cite

show abstract

“…103 Kinase inhibitors, such as hypericin or herbimycin, have shown positive results in preclinical PVR studies. 104,105 Alkylphosphocholine is an inhibitor of protein kinase C shown to be effective against RPE cell attachment, migration, and proliferation in vitro . 106 AG1295, an inhibitor of PDGFR kinase, significantly attenuated the development of retinal detachment without histologic or functional damage to the retina.…”

Section: Introductionmentioning

confidence: 99%

Proliferative Vitreoretinopathy: A Review

Idrees

Sridhar

Kuriyan

2019

International Ophthalmology Clinics

180

169

View full text Add to dashboard Cite

Proliferative vitreoretinopathy (PVR) is the most common cause for failure of rhegmatogenous retinal detachment repair and is characterized by the growth and contraction of cellular membranes within the vitreous cavity and on both sides of the retinal surface as well as intraretinal fibrosis. Currently, PVR is thought to be an abnormal wound healing response that is primarily driven by inflammatory, retinal, and RPE cells. At this time, surgery is the only management option for PVR as there is no proven pharmacologic agent for the treatment or prevention of PVR. Laboratory research to better understand PVR pathophysiology and clinical trials of various agents to prevent PVR formation are ongoing.

show abstract

“… Glucosamine is an aminomonosaccharide that suppresses RPE proliferation in vitro, interfering with the TGF-β signaling pathway [ 116 ]. Hypericin and herbimycin A were effective in preclinical studies by reducing PVR development in animal models of RD [ 117 , 118 ]. Alkylphosphocholine is a protein kinase C inhibitor that was shown to be effective against RPE migration and proliferation in vitro [ 119 ].…”

Section: Therapeutic Strategiesmentioning

confidence: 99%

“…Hypericin and herbimycin A were effective in preclinical studies by reducing PVR development in animal models of RD [ 117 , 118 ].…”

Section: Therapeutic Strategiesmentioning

confidence: 99%

Proliferative Vitreoretinopathy: A Reappraisal

Carpineto

Licata

Ciancaglini

2023

JCM

View full text Add to dashboard Cite

Proliferative vitreoretinopathy (PVR) remains the main cause of failure after retinal detachment (RD) surgery. Despite the development of modern technologies and sophisticated techniques for the management of RD, the growth of fibrocellular membranes within the vitreous cavity and on both sides of the retinal surface, as well as intraretinal fibrosis, can compromise surgical outcomes. Since 1983, when the term PVR was coined by the Retina Society, a lot of knowledge has been obtained about the physiopathology and risk factors of PVR, but, despite the proposal of a lot of therapeutic challenges, surgical skills seem to be the only effective way to manage PVR complications.

show abstract

Estudo experimental da inibição da proliferação vitreorretiniana pelo uso da hiperecina

Cited by 5 publications

References 25 publications

Proliferative vitreoretinopathy: current and emerging treatments

Proliferative vitreoretinopathy: current and emerging treatments

Proliferative Vitreoretinopathy: A Review

Proliferative Vitreoretinopathy: A Reappraisal

Contact Info

Product

Resources

About